Merz Aesthetics Strengthens Global Footprint with Launch of XEOMIN and RADIESSE in China
Published: 17 Dec 2025
Author: Precedence Research
Merz Aesthetics, the world’s largest dedicated medical aesthetics company, has taken a major step in its global expansion strategy. They launched their flagship injectable products, XEOMIN (incobotulinumtoxinA) and RADIESSE, in China. The company is entering one of the most dynamic and fastest-growing medical aesthetics markets worldwide. It aims to meet the increasing demand from Chinese patients and practitioners for advanced, clinically proven aesthetic procedures. This achievement underscores Merz Aesthetics' long-term strategy of expanding access to its high-quality aesthetic innovations and maintaining its position as a category leader in the international market.
China is a key driver in the global growth of the aesthetics industry due to increasing consumer awareness. The Chinese population is highly receptive to aesthetic treatments, and clinical practices are evolving. Merz Aesthetics is entering a new and rapidly expanding market with internationally recognized standards of quality, safety, and patient-centered innovation through the launch of XEOMIN and RADIESSE. This also shows how the company has positioned itself to enter high-demand areas that are experiencing growth in scientifically based, differentiated injectables.
XEOMIN is a purified botulinum toxin developed by Merz Aesthetics, distinguished in its category of neurotoxins for being double-purified. XEOMIN is produced using proprietary XTRACT Technology, which removes undesired complexing proteins, leaving the active neurotoxin and two stabilizing components that do not induce immune responses. This highly advanced formulation has demonstrated zero resistance to toxins in key clinical trials. It offers a reliable option for patients seeking long-lasting and consistent aesthetic results. Additionally, Merz Aesthetics plans to expand its presence in China by increasing educational programs, strengthening clinical partnerships, and introducing new innovations tailored to local needs.
Executive Statement
Bob Rhatigan, Chief Executive Officer of Merz Aesthetics, said: "China is a key strategic market for our global business, and this launch marks an important milestone in our journey as a category leader. Since becoming a standalone company in 2020, we have consistently outpaced the industry by focusing on innovation, quality, and patient needs. Introducing XEOMIN and RADIESSE to China strengthens our commitment to expanding access to premium, clinically proven aesthetic solutions worldwide.”